

Suven Life Sciences Presenting Clinical Data of NCEs at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025, San Diego, USA.

Hyderabad, India (1-Dec-2025): Suven Life Sciences Limited, a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for Central Nervous System (CNS) disorders, today announced the presentation of clinical posters highlighting its advanced new chemical entities (NCEs) at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025, taking place in San Diego, USA and virtually during December 1–4, 2025.

The Clinical Trials on Alzheimer's disease (CTAD) Conference, established in 2008, is a leading global forum dedicated to advancing Alzheimer's disease clinical research. It fosters close collaboration among researchers through science-focused setting. The 18th annual CTAD-2025 continuing to showcase rapid progress in AD therapeutics. The program includes expert-led symposia and roundtables on emerging approaches. All presentations undergo rigorous peer review, ensuring high-quality scientific contributions that shape the future of AD research.

Suven senior scientific team will meet several principal investigators of the ongoing global phase-3 trial of Masupirdine (SUVN-502) to discuss various strategies to further accelerate the enrollment and progress the study to completion rapidly.

Suven Presentations

- **Masupirdine (A Pure 5-HT₆ Receptor Antagonist): Update on the Phase-3 Clinical Study Targeting Agitation in Patients with Dementia of Alzheimer's Type.**
- **SUVN-I6107, a True Positive Allosteric Modulator at Muscarinic M₁ Receptor for Treatment of Cognitive Disorders, Update on the Development.**

About Suven Life Sciences: Suven Life Sciences Limited (Suven) is focused on the drug discovery and clinical development of innovative medicines that address unmet medical needs in CNS disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase2a study completed; Double blind randomized Placebo controlled Phase-2b study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad - 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

planning), SUVN-I6107 for cognitive disorders (Phase-1 study in progress). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website <http://www.suven.com>

Risk Statement: Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad - 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com